

CUMBERLAND PHARMACEUTICALS INC  
Form 8-K  
April 26, 2019

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of  
Report  
(Date of  
Earliest  
Event  
Reported):  
April 26,  
2019  
(April 23,  
2018)

---

CUMBERLAND PHARMACEUTICALS INC.  
(Exact name of registrant as specified in its charter)

Tennessee                                  001-33637                                  62-1765329  
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

2525 West End Avenue, Suite 950, Nashville, Tennessee 37203  
(Address of principal executive offices) (Zip Code)

(615) 255-0068  
(Registrant's telephone number, including area code)

Not Applicable  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

---

Item 5.07 Submission of Matters to a Vote of Security Holders.

On April 23, 2019, the annual meeting of shareholders of Cumberland Pharmaceuticals Inc. (the "Company") was held in Nashville, Tennessee. The following matter was voted upon and approved by the Company's shareholders: (1) the election of four (4) Class III Directors to serve until the 2022 Annual Meeting of Shareholders, or until their successors are duly elected and qualified.

The voting results were as follows:

	For	Against	Withheld	% of votes in favor
A.J. Kazimi	11,016,085	0	91,484	99.2%
Martin E. Cearnal	10,993,980	0	113,589	99.0%
Gordon R. Bernard	10,790,830	0	316,739	97.1%
Joseph C. Galante	11,032,236	0	75,333	99.3%

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

Date: April 26, 2019 By: /s/ Michael Bonner

Name: Michael Bonner

Title: Chief Financial Officer